|
|
|
- つねとき わくや
- 9 years ago
- Views:
Transcription
1 5.3mg ()
2
3 1
4 2SD 2 1.5SD
5 4 4 3 ( ) 瘙 3
6 嘔 気 嘔 吐 腹 痛 消 化 不 良 便 秘 4
7 24 p * p ** IGF-I (ng/ml) 77.12± ± ± [124.08, ] (p<0.0001) [119.27, ] (p<0.0001) 83.33± ± ±22.16 [-3.27, 11.73] (p=0.2672) * Wilcoxon SD [ 95%] **Wilcoxon : DXA 48 % / 43.85± ± ±4.23 [-0.20, 2.71] kg / 40.41± ± ±5.94 [2.65, 6.67] SD [ 95%] mg /kg/ ± ±10.30 kg 39.93± ±11.01 % p * 4.72±5.25 [2.97, 6.47] (p<0.0001) 1.03±4.38 [-0.45, 2.51] (p=0.1338) % p ** 3.69 [1.43, 5.95] (p=0.0003) * Wilcoxon SD [ 95%] **Wilcoxon 48 IGF-I / ± ± ± [ , -9.99] ng/ml / 87.56± ± ±96.94 [83.38, ] SD [ 95%] /35 /36 : DXA 5
![033 mg /kg/ 24 41.48±9.77 43.38±10.30 kg 39.93±10.34 40.41±11.01 % p * 4.72±5.25 [2.97, 6.47] (p<0.0001) 1.03±4.38 [-0.45, 2.51] (p=0.1338) % p ** 3.69 [1.43, 5.95] (p=0.](/docs-images/43/23109301/images/page_7.jpg "0003) * Wilcoxon SD [ 95%] **Wilcoxon 48 IGF-I / 249.30±140.71 190.18±73.16-59.13±143.05 [-108.27, -9.99] ng/ml / 87.56±54.66 203.74±91.01 116.18±96.94 [83.38, 148.")
8 ö 6
9 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg ()
10
11 ( ) () D- D- () () D- D- 1
12 2SD 2 1.5SD
13 IGF-I
14 瘙 4 嘔 気 嘔 吐 腹 痛 消 化 不 良 便 秘
15 ± ±10.30 kg 39.93± ±11.01 % p * 4.72±5.25 [2.97, 6.47] (p<0.0001) 1.03±4.38 [-0.45, 2.51] (p=0.1338) % p ** 3.69 [1.43, 5.95] (p=0.0003) * Wilcoxon SD [ 95%] **Wilcoxon 24 p * p ** IGF-I (ng/ml) 77.12± ± ± [124.08, ] (p<0.0001) [119.27, ] (p<0.0001) 83.33± ± ±22.16 [-3.27, 11.73] (p=0.2672) * Wilcoxon SD [ 95%] **Wilcoxon : DXA 48 % / 43.85± ± ±4.23 [-0.20, 2.71] kg / 40.41± ± ±5.94 [2.65, 6.67] SD [ 95%] 48 IGF-I / ± ± ± [ , -9.99] ng/ml / 87.56± ± ±96.94 [83.38, ] SD [ 95%] /35 /36 : DXA 5
![51 87.56±54.66 4.23±22.16 [-3.27, 11.73] (p=0.2672) * Wilcoxon SD [ 95%] **Wilcoxon : DXA 48 % / 43.85±10.26 44.38±10.41 1.25±4.23 [-0.20, 2.71] kg / 40.41±11.01 42.14±11.02 4.](/docs-images/43/23109301/images/page_15.jpg "66±5.94 [2.65, 6.67] SD [ 95%] 48 IGF-I / 249.30±140.71 190.18±73.16-59.13±143.05 [-108.27, -9.99] ng/ml / 87.56±54.66 203.74±91.01 116.18±96.94 [83.38, 148.")
16 3 ö 6
17 12mg ()
18
19 1 2SD
20 2 1.5SD
21 4 43 瘙 3
22 嘔 気 嘔 吐 腹 痛 消 化 不 良 便 秘 mg 5.3 mg Cmax miu/lauc miuhr/ltmax hrt1/ hr 5.3 mg 5.3 mg 8 (2.8 mg ) mg
23 ± ±10.30 kg 39.93± ±11.01 % p * 4.72±5.25 [2.97, 6.47] (p<0.0001) 1.03±4.38 [-0.45, 2.51] (p=0.1338) % p ** 3.69 [1.43, 5.95] (p=0.0003) * Wilcoxon SD [ 95%] **Wilcoxon 24 p * p ** IGF-I (ng/ml) 77.12± ± ± [124.08, ] (p<0.0001) [119.27, ] (p<0.0001) 83.33± ± ±22.16 [-3.27, 11.73] (p=0.2672) * Wilcoxon SD [ 95%] **Wilcoxon : DXA 48 % / 43.85± ± ±4.23 [-0.20, 2.71] kg / 40.41± ± ±5.94 [2.65, 6.67] SD [ 95%] 48 IGF-I / ± ± ± [ , -9.99] ng/ml / 87.56± ± ±96.94 [83.38, ] SD [ 95%] /35 /36 : DXA ö 5
24 6
25 1.8.2 Page (1) (2) (1) 2 3 ng/ml GHRP-2 15 ng/ml 1 3 ng/ml GHRP-2 15 ng/ml (2) ng/ml GHRP-2 15 ng/ml 1.8 ng/ml GHRP-2 9 ng/ml
26 1.8.2 Page 2 Carroll Rosen GH GH GH GH AGHD GH AGHD GT37P36 24 p= p= p= (%) p * p ** GT p< p= P p= GT ± ± ±11.79 p< P= P ± ± ±7.11 p= *Wilcoxon SD **Wilcoxon
27 1.8.2 Page p * p ** LDL-mg/dL GT ± ± ±19.6 p= p= P ± ± ±23.1 p= HDL-mg/dL GT ± ± ±8.7 p= p= P ± ± ±8.4 p= mg/dl GT ± ± ±21.8 p= p= P ± ± ±23.9 p= *Wilcoxon SD **Wilcoxon , 6-3, 6-5, 6-7, 6-9, GH GH 3ng/mL EU AGHD GH QOL IGF-I 2SDS1
28 1.8.2 Page (1) (2) (1) 2 3 ng/ml GHRP-2 15 ng/ml 1 3 ng/ml GHRP-2 15 ng/ml (2) ng/ml GHRP-2 15 ng/ml 1.8 ng/ml GHRP-2 9 ng/ml Growth Hormone Research Society AGHD GH GH AGHD AGHD
29 1.8.2 Page 5 GH GH GH (1) : (2): GH pulsatile GH AGHD GH AGHD GH GH (1) 2 3 ng/ml GHRP-2 15 ng/ml 1 3 ng/ml GHRP-2 15 ng/ml AGHD GH GH (2) ng/ml GHRP-2 15 ng/ml 1.8 ng/ml GHRP-2 9 ng/ml GH
30 1.8.2 Page %: GT 24 p * kg ± ± ± ±11.73 kg 4.37±6.25 p= ±4.07 p= ± ± ±12.74 p= ± ± ±10.96 p= *Wilcoxon , 3-5 P 24 p * ± ± ± ± ± ± ± ± ±4.38 p= ±4.32 p= ±7.04 p= ±7.22 p= SD LDL-mg/dL : GT 24 p * ± ± ±17.3 p= ± ± ±22.4 p= *Wilcoxon P 24 p * ± ± ±26.7 p= ± ± ±18.8 p= SD
31 1.8.2 Page GH GH GH GH GH IGF-I GH AGHD kg 0.084mg IGF-I AGHD GH IGF-I IGF-I IGFBP-3 ALS (acid labile subunit)
32 1.8.2 Page 8 IGF-I IGF-I GH /3 GH IGF-I 17 ~ <20 20 ~ <30 30 ~ <40 40 ~ <50 50 ~ <60 60 ~ < IGF-I IGF-I ng/ml * ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 226 *1.96 SD IGF-I SDS mg/kg/ mg/kg/ mg/kg/ GHD 1/8 1/41/ mg/kg/ 8 IGF-I 1.0 mg/076
33 1.8.2 Page mg/kg/ mg/kg/ mg/kg/ mg/kg/08 IGF-I IGF-I SDS IGF-I SDS IGF-I IGF-I SDS IGF-I IGF-I SD IGF-I SDS GT mg/kg/ 8 0 SD mg/kg/ SD SD GT IGF-I IGF-I IGF-I SDS mg/kg/ GT ± ± ± ± ±2.390 (n=37) [-2.505, ] [-1.084, 0.152] [-0.244, 1.133] [0.664, 2.184] [0.021, 1.615] P ± ± ± ± ±1.345 (n=36) [-2.268, ] [-2.207, ] [-2.245, ] [-2.296, ] [-2.201, ] SD95%
34 1.8.2 Page 10 SDS 8 GT P GT IGF-Ing/mL 075 GT IGF-I IGF-I 24 * ± ~ ± ~ ~ < ± ~ ± ~ ± ~ ~ < ± ~ ~ ~ < ± ~ ~ <60 42 ~ ~ <70 46 ~ ~ < ± ~ ~ <60 37 ~ ~ <70 43 ~ ~ < ± ~ ~ <60 *1.96 SD 35 ~ ~ <70 SD 075 GT IGF-I SDS IGF-I SDS +2SD GT 38 19
35 1.8.2 Page 11 IGF-I SDS GT IGF-I SDS mg/kg/ 8 IGF-I 1.0 mg/ 48 GT/GT P/GT mg/kg/ mg/kg/ mg/kg/ mg/kg/ 076 P/GT IGF-I SDS IGF-I SD P/GT IGF-I IGF- I <60 60< IGF-I SDS ± ± ± ± ± ± ±1.491 GT/GT [0.164, [-0.876, [-1.141, [-0.624, [-0.141, [-0.177, [-0.055, N= ] 0.336] 0.188] 0.603] 0.976] 0.977] 0.970] P/GT N= ± ± ± ± ± ± ±1.269 [-2.201, ] [ ] [-0.848, 0.105] [-0.397, 0.381] [-0.257, 0.639] [-0.098, 0.966] [0.013, 0.872] SD95%
36 1.8.2 Page P/GT IGF-Ing/mL 076 P/GT IGF-I IGF-I * 48 ** ± ~ ± ~ ~ < ± ~ ± ~ ± ~ ~ < ± ~ ~ ~ < ± ~ ~ <60 42 ~ ~ <70 46 ~ ~ < ± ~ ~ <60 37 ~ ~ <70 43 ~ ~ < ± ~ ~ <60 35 ~ ~ <70 *075 **1.96 SD SD 076 IGF-I SDS GT/GT mg/kg/ mg/kg/ mg/kg/+2sd +2SD 075 P/GT IGF-I SDS 24 +2SD IGF-I GT/GT P/GT IGF-I SDS
37 1.8.2 Page IGF-I IGF-I GH IGF-I GH 4 IGF-I 076 P/GT ( )12 IGF-I %(14 /33 )20 IGF-I %(28 /33 ) -4 mg/ (mg/) (mg/) (mg/) (mg/) (mg/) (mg/) (mg/)
38 1.8.2 Page 14-4 mg/ (mg/) (mg/) (mg/) (mg/) (mg/) (mg/) (mg/) (: ) ( ) IGF-I4 IGF-I1212 IGF-I 24IGF-I IGF-IGH GH P/GT LDL GT LDL P/GT GT/GT
39 1.8.2 Page (kg) (kg) GT ± ± ±10.30 P ± ± ±11.01 GT ± ± ±7.54 P ± ± ±7.32 LDL- GT ± ± ± ± ±32.0 (mg/dl) P ± ± ± ± ± , 2-1, P/GT SD (kg) ± ± ±11.02 (kg) ± ± ±7.28 LDL ± ± ± ± ± ± ± ±32.1 (mg/dl) , 5.2.1, SD mg/kg/ 075 GT 10%8 21.6% %4 10.8% GT 2 5.4% GT GT 2 5.4%
40 1.8.2 Page GT mg/ # # # mg/ * * * * mg/ mg/ mg/ ** 36 # mg/kg/ mg/kg/ * ** %P/GT %GT/GT % % %5 14.3%4 11.4%4 11.4% % GOT ASTGOT4 11.4%4 11.4% GT/GT P/GT P/GT 1 GT/GT GT/GT P/GT 1 GT/GT %P/GT % 8 GT/GT %P/GT %
41 1.8.2 Page 17 GT/GT * mg GT/GT mg/ AST GOT ALTGPT mg/ mg/ mg/ mg/ CM ** mg/ mg/ * 1 mg/ 1kg mg/kg/ mg/kg/ mg/kg/ mg/kg/ ** # 076 1
42 1.8.2 Page 18 P/GT * mg P/GT mg/ a) mg/ mg/ ** a a GTP mg/ AST(GOT) b) 0.5 mg/ ALT(GPT) * 1 mg/ 1kg mg/kg/ mg/kg/ mg/kg/ mg/kg/ ** # a) b) mg/kg/ mg/ mg/kg/ P/GT GT/GT 1 P/GT mg/ GT/GT mg/ GT % % mg/kg/8 24 I IGF-I SDS SD
43 1.8.2 Page P/GT %2 8.3%3 075 GT 075 P/GT IGF-I 076 GT/GT % % mg/kg/ () mg/kg/ () mg/kg/ () IGF-I * IGF-I (ng/dl) SDS IGF-I (ng/dl) SDS * GT 43.2% P/GT 30.8%8 GT/GT 22.2% GT P/GT GT/GT
44 1.8.2 Page GH mg/ mg/ kg mg/ 80 kg kg mg/kg/ mg/kg/ mg/kg/ IGF-I SDS 0.003mg/kg/ IGF-I SDS 0.003mg/kg/ a) I GT P P/GT GT P GT P GT P ASTGOT ALTGPT GTP T T
45 1.8.2 Page I GT P P/GT GT P GT P GT P a) kg 0.003mg mg/ 1 mg/ 1 1 mg/ 6 3, AGHD
46 1.8.2 Page
47 1.8.2 Page P/GT ( )12 IGF-I %(14 /33 )20 IGF-I %(28 /33 ) IGF-I 4 IGF-I IGF-I 24 IGF-I IGF-I GH GH IGF-I GH
48 1.8.2 Page CDS 1 2SD 2 1.5SD [ ]
49 1.8.2 Page
50 1.8.2 Page 26 (1) 2SD mg// SD [ ]
51 1.8.2 Page 27 (1) 1) 2) 3) 4) IGF-I
52 1.8.2 Page
53 1.8.2 Page 29 瘙
54 1.8.2 Page 30 嘔 気, 嘔 吐, 腹 痛, 消 化 不 良, 便 秘
55 1.8.2 Page 31
56 1.8.2 Page mg
57 1.8.2 Page AGHD AGHD KIGS, KIMS GH AGHD KIMS AGHD ACTH 6.1%, 2.7%, 2.9%, 5.0% KIMS (6.1) ACTH (2.7) (2.9) 44 1 (2.2) (5.0) (14.4) 12 4 (33) (3.6) 50 2 (4) GHD GHD GH GH GH %GH KIMS GH GH
58 1.8.2 Page 34 AGHD
59 1.8.2 Page 35 KIGS Pfizer International Growth Database KIMS Pfizer Internatioal Metabolic Database IGFs 076 IGF-I SDS IGF-I SDS IGF-I SDS -1.96SDS1.96SDS IGF-I SDS IGF-I SDS IGF-I SDS 076 IGF-I SDS IGF-I IGF-I SDS GH IGF-I SDS IGF-I IGF-I IGF-I SDS
60 1.8.2 Page 36 HbA 1C HbA 1C 075 GT mg/kg/(8-24 ) (0-4 ) mg/kg/ () mg/kg/ () mg/kg/ () CTD P/GT( ) %075 GT IGF-I AGHD AGHD
61 1.8.2 Page GT GT A GH
62 1.8.2 Page a) / / GT P GT P % % % ASTGOT ALTGPT GTP T
63 1.8.2 Page / / GT P GT P % % % a) GH IGF-I
64 1.8.2 Page IGF-I IGF-I
65 1.8.2 Page 41 1) Carroll PV, Christ ER and the members of Growth Hormone Research Society Scientific Committee. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998; 83 (2): ) Rosén T, Bengtsson BÅ. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: ). GH. 6 ; ). GH. 16 ; ) Invited report of a workshop; Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998; 83 (2): ),,,,,,. IRMA IGF-I, IGF-II, IGFBP-3 : ; 44: ) Drake WM, Coyte D, Camacho-Hübner C, Jivanji NM, Kaltsas G, Wood D.F. et al. Optimizing Growth Hormone Replacement Therapy by Dose Titration in Hypopituitary Adults. Journal of Clinical Endocrinology and Metabolism 1998; 83(11): ),,. : 1., ;
LDL HbA1c6. 5% AST51 ALT51 - GT LDL180 1, mmHg 85mmHg 150mg/dL HDL 40mg/dL 100mg/dL HbA1c 5.6% mmhg mg/dl mg/
30 7 IT 28 335 704 4 16 40-74 1 3 1100cm 2 100cm 2 BMI25kg/m 2 285cm 90cm 385cm 90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL
本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
untitled
280 200 5 7,800 6 8,600 28 1 1 18 7 8 2 ( 31 ) 7 42 2 / / / / / / / / / / 1 3 (1) 4 5 3 1 1 1 A B C D 6 (1) -----) (2) -- ()) (3) ----(). ()() () ( )( )( )( ) ( ) ( )( )( )( ) () (). () ()() 7 () ( ) 1
[] 1
![[] 1](/thumbs/42/22960844.jpg "[] 1")
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61
<82D282A982C1746F95F18D908F57967B95B E696E6464>
1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9
180 140 22
21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3
BAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
MultiWriter 5600C 活用マニュアル
1 *1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 9 1 2 3 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 1 2 3 a b c 26 27 28 C *1 *2 *2 29 2 2 2 2 2 2 2 2 2 30 *1 *2 ± *1 C C 31 32 33 34 35 36 M C Y K 1 2 3 4 5 6
untitled
5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
10 4 2
1 10 4 2 92 11 3 8 20 10 2 10 20 10 28 3 B 78 111 104 1021 95 10 2 4 10 8 95 18 10 30 11 13 104 20 105 105 105 105 107 5 1 11 26 13301500 6 GH 1 GH 34 7 11 27 9301030 8 4 9 GH 1 23 10 20 60 --------------------------------------------------------------------------------------------------------------------------
14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0
... 3... 3... 3... 3... 4... 7... 10... 10... 11... 12... 12... 13... 14... 15... 18... 19... 20... 22... 22... 23 2
1 ... 3... 3... 3... 3... 4... 7... 10... 10... 11... 12... 12... 13... 14... 15... 18... 19... 20... 22... 22... 23 2 3 4 5 6 7 8 9 Excel2007 10 Excel2007 11 12 13 - 14 15 16 17 18 19 20 21 22 Excel2007
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
SBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
http://banso.cocolog-nifty.com/ 100 100 250 5 1 1 http://www.banso.com/ 2009 5 2 10 http://www.banso.com/ 2009 5 2 http://www.banso.com/ 2009 5 2 http://www.banso.com/ < /> < /> / http://www.banso.com/
68 22 Proceeding Clinical features and diagnosis of lymphocytic infundibulo-hypophysitis IgG4 12 / 7/ IgG4 3/7 IgG
68 22 Proceeding Clinical features and diagnosis of lymphocytic infundibulo-hypophysitis IgG4 12 /7/5 26 78 2 4 6 11 11 IgG4 3/7 IgG4 2 21 1 1 1 4 4 2 5 3 IgG4 IgG4 IgG4 IgG4 MR 1 Tolosa-Hunt IgG4 2 IgG4
untitled
COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5
200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
n=360 28.6% 34.4% 36.9% n=360 2.5% 17.8% 19.2% n=64 0.8% 0.3% n=69 1.7% 3.6% 0.6% 1.4% 1.9% < > n=218 1.4% 5.6% 3.1% 60.6% 0.6% 6.9% 10.8% 6.4% 10.3% 33.1% 1.4% 3.6% 1.1% 0.0% 3.1% n=360 0% 50%
Page 1
Page 1 Page 2 Page 3 Page 4 620 628 579-41 -6.7-49 -7.9 71 41 47-24 -33.3 6 15.9 11.5 6.5 8.1 36 15 22-14 -38.9 7 43.4 Page 5 277 302 23 24 12/3Q 12/4Q 13/1Q 13/2Q 13/3Q 13/4Q 14/1Q 14/2Q 14/3Q 14/4Q 15/1Q
8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
TRS4505.ec6..
糖尿病の療養指導 211 [ 日本糖尿病学会編 ] 別刷 レクチャー : 糖尿病療養指導に必要な知識 1 5 食後高血糖と脂質異常症の同時評価, 是正とその意義 原納 優, 前田亜耶, 名引順子, 原納晶著 211 年 9 月発行 発行所株式会社 診断と治療社 21 5 1 13 1,2 4 1 1 2 3 4 Key Words CMT Summary 154 CMT 1 IGT2 IFG3 1
慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
項 目
1 1 2 3 11 4 6 5 7,000 2 120 1.3 4,000 04 450 < > 5 3 6 7 8 9 4 10 11 5 12 45 6 13 E. 7 B. C. 14 15 16 17 18 19 20 21 22 23 8 24 25 9 27 2 26 6 27 3 1 3 3 28 29 30 9 31 32 33 500 1 4000 0 2~3 10 10 34
保健医療学学会 第３回学術集会 学術大会抄録集 会 期 ２０１２年１２月２日(日) 会 場 大阪電気通信大学 駅前キャンパス 京阪寝屋川市駅 集会長 小柳 磨毅 大阪電気通信大学 医療福祉工学部 教授 主 催 保健医療学学会 共 催 大阪電気通信大学 後 援 (社)大阪府理学療法士会 (社)大阪府作業療法士協会 ..... 24 23 2 3 1 12 CAVI BMI QOL SF-36
2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
